The association of PGC-1α and its single-nucleotide polymorphism with the lipid metabolic disorders of diabetic kidney disease in patients with type 2 diabetes

Abstract

Aim: This study aimed to explore the correlation between peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and diabetic kidney disease (DKD) susceptibility in the Han Chinese population.

Methods: The distribution of Gly482Ser (rs8192678) and its relationship with blood PGC-1α messenger RNA (mRNA) expression were examined in healthy volunteers, patients with type 2 diabetes mellitus (T2DM), and those with DKD. The single-nucleotide polymorphism was genotyped using a DNA extraction kit and TaqMan-minor groove binder (MGB) probe real-time polymerase chain reaction.

Results: We enrolled 574 subjects: 212 healthy controls, 186 with T2DM, and 176 with DKD. The rs8192678 AA genotype was more frequent in controls than in T2DM or DKD groups (P < 0.001). Under additive, dominant, and recessive models, the GG genotype was linked to higher T2DM risk after age and sex adjustment (P < 0.001), but not to progression from T2DM to DKD. PGC-1α mRNA levels were also higher in AA carriers than in GG carriers across all groups (P < 0.05).

Conclusion: Our study identifies the G allele of PPARGC1A rs8192678 as a risk factor for T2DM, but its role in DKD is context-dependent. Although not a risk factor in the general T2DM population, this allele is linked to higher DKD risk specifically in patients with normal triglyceride levels. This association was driven by the GA and AA genotypes, not the GG genotype, highlighting the complex interplay between genetics and metabolic state in DKD.

Keywords

Diabetic kidney disease / PGC-1α / single-nucleotide polymorphism / type 2 diabetes

References

[1] Duan J,Zhao Z.Short-term duration of diabetic retinopathy as a predictor for development of diabetic kidney disease.J Transl Int Med2023;11:449-58 PMCID:PMC10732346

[2] Liu D,He W.Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy.Integr Med Nephrol Androl2024;11:e23-00029

[3] Zhao H,Li P.Gut microbiota-derived metabolites: a new perspective of traditional chinese medicine against diabetic kidney disease.Integr Med Nephrol Androl2024;11:e23-00024

[4] Zhao H,Yan M.Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle.J Transl Int Med2024;12:157-69

[5] Chung JY,Tang PM.New insights into traditional chinese medicine in treatment of diabetic nephropathy.Integr Med Nephrol Androl2023;10:e00026

[6] Wu C,Zhang R.Research progress on Cornus officinalis and its active compounds in the treatment of diabetic nephropathy.Front Pharmacol2023;14:1207777 PMCID:PMC10354237

[7] Zhang R,Wu C,Liu P.Lipidomics-based natural products for chronic kidney disease treatment.Heliyon2025;11:e41620 PMCID:PMC11758422

[8] Deng Y,Xing J.The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease.Front Physiol2025;16:1624077 PMCID:PMC12234459

[9] Ma L,Kong X.Association of EPHX2 R287Q polymorphism with diabetic nephropathy in Chinese type 2 diabetic patients.J Diabetes Res2018;2018:2786470

[10] Trombetta M,Boselli ML.PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the verona newly diagnosed type 2 diabetes study (VNDS) 4.Acta Diabetol2013;50:401-8

[11] Yang R,Wang L.Prediction and identification of power performance using polygenic models of three single-nucleotide polymorphisms in Chinese elite athletes.Front Genet2021;12:726552 PMCID:PMC8532995

[12] Du F,Piao LS.Correlation between PPARGC1A gene Rs8192678 G>A polymorphism and susceptibility to type-2 diabetes.Open Life Sci2019;14:43-52 PMCID:PMC7874819

[13] Xia W,Peng W.Systematic meta-analysis revealed an association of PGC-1α rs8192678 polymorphism in type 2 diabetes mellitus.Dis Markers2019;2019:2970401

[14] Seman N, Othman SH. Recent progress in genetics and epigenetics research on diabetic nephropathy in Malaysia.J Diabetes Res2023;2023:9053580 PMCID:PMC10181909

[15] Alberti KGMM, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation.Diabet Med1998;15:539-53

[16] Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int2022;102:S1-S127

[17] Committee on the Chinese Guidelines for Lipid Management. Chinese guideline for lipid management (primary care version 2024).Chin J Cardiol2024;52:330-7

[18] Carvalho MO,Huguenin GVB,Rodrigues Júnior LF.Increased cardiometabolic risk in dynapenic obesity: results from the study of workers’ health (ESAT).Life2024;14:1174 PMCID:PMC11433080

[19] Liu P,Zhao H.Association between LXR-α and ABCA1 Gene Polymorphisms and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus in a Chinese Han Population.J Diabetes Res2020;2020:8721536 PMCID:PMC7772016

[20] Freedman BI,Lu L.Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.PLoS Genet2011;7:e1002150 PMCID:PMC3116917

[21] Wang H,Yu M,Wei Y.PGC-1α in osteoarthritic chondrocytes: From mechanism to target of action.Front Pharmacol2023;14:1169019 PMCID:PMC10117990

[22] Savla SR,Bhatt LK.Liver X receptor: a potential target in the treatment of atherosclerosis.Expert Opin Ther Targets2022;26:645-58

[23] Rasheed A.Beyond the foam cell: the role of LXRs in preventing atherogenesis.Int J Mol Sci2018;19:2307 PMCID:PMC6121590

[24] Ahsan F,Goud HK.Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Cureus2020;12:e10446 PMCID:PMC7557526

[25] Luo L,Liu T.Muscle injuries induce a prostacyclin-PPARγ/PGC1a-FAO spike that boosts regeneration.Adv Sci2023;10:e2301519

[26] Ahrens M,von Schönfels W.DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery.Cell Metab2013;18:296-302

[27] Chambers JM.PGC-1α in disease: recent renal insights into a versatile metabolic regulator.Cells2020;9:2234 PMCID:PMC7601329

[28] Besse-Patin A,Oropeza D,Prat A.Estrogen signals through peroxisome proliferator-activated receptor-γ coactivator 1α to reduce oxidative damage associated with diet-induced fatty liver disease.Gastroenterology2017;152:243-56

[29] Ghosh S,Lefort N.Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose tolerance.Diabetes2011;60:2051-60 PMCID:PMC3142073

[30] Hammarstedt A,Wesslau C,Smith U.Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance.Biochem Biophys Res Commun2003;301:578-82

[31] Zhang RN,Pan Q,Chen GY.PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.World J Gastroenterol2021;27:3863-76 PMCID:PMC8291025

[32] Lin YC,Chang MH.A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children.Am J Clin Nutr2013;97:326-31

[33] Goyenechea E,Abete I,Martínez JA.Enhanced short-term improvement of insulin response to a low-caloric diet in obese carriers the Gly482Ser variant of the PGC-1alpha gene.Diabetes Res Clin Pract2008;82:190-6

[34] Geloneze SR,Morari J.PGC1α gene Gly482Ser polymorphism predicts improved metabolic, inflammatory and vascular outcomes following bariatric surgery.Int J Obes2012;36:363-8